Tecvayli (teclistamab-cqyv) / Genmab, J&J 
Welcome,         Profile    Billing    Logout  

38 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tecvayli (teclistamab-cqyv) / Genmab, J&J
NCT06251076: Plan Development for Giving Teclistamab in the Outpatient Setting

Not yet recruiting
4
15
NA
Teclistamab, TECVAYLI, Tocilizumab, ACTEMRA
University Health Network, Toronto, Janssen Inc.
Multiple Myeloma, Relapsed Cancer, Refractory Cancer
04/25
09/25
2020-004742-11: A randomized phase 3 study of Teclistamab in combination with daratumumab verses an Investigators choice of Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Velcade, Dexamethasone in Relapsed or Refractory Multiple Myeloma

Ongoing
3
560
Europe
Teclistamab, Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20), Imnovid, Dexamethasone, Velcade, JNJ-64007957, JNJ-54767414, Solution for injection, Capsule, Powder for solution for injection, Darzalex, Imnovid, Neofordex, Velcade
Janssen-Cilag International NV, Janssen Research & Development, LLC
Multiple Myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
2022-000909-28: A randomized phase 3 study of Teclistamab in combination withdaratumumab and lenalidomide versus a combination of daratumumab, lenalidomide and dexamethasone in new multiple myeloma patients who cannot undergo stem cell transplant as the first therapy.

Ongoing
3
1030
Europe
Teclistamab, Daratumumab, Lenalidomide Accord, JNJ-64007957, JNJ-54767414, Solution for injection, Capsule, Darzalex, Lenalidomide Accord
Janssen-Cilag International NV, Janssen Research & Development, LLC
Multiple Myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
2022-000928-37: A Clinical Study to Compare Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide

Not yet recruiting
3
590
Europe, RoW
Teclistamab, Pomalidomide, Bortezomib, Carfilzomib, Dexamethasone, JNJ-64007957, Solution for injection, Capsule, Powder for solution for injection, Powder for solution for infusion, Tablet, TECVAYLI, Imnovid, VELCADE, Kyprolis, Dexamethasone Aspen, Dexamethasone JENAPHARM, Dexamethasone GALEN
Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development, LLC, Janssen-Cilag SpA
Multiple myeloma, Multiple myeloma, Diseases [C] - Cancer [C04]
 
 
MonumenTAL-6, NCT06208150: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Recruiting
3
795
Europe, Canada, Japan, RoW
Talquetamab, JNJ-64407564, Talvey, Pomalidomide, Pomalyst, Imnovid, Teclistamab, JNJ-64007957, Tecvayli, Elotuzumab, Empliciti, Dexamethasone, Bortezomib, Velcade
Janssen Research & Development, LLC
Relapsed or Refractory Multiple Myeloma
04/26
06/30
MajesTEC-3, NCT05083169 / 2020-004742-11: A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

Active, not recruiting
3
587
Europe, Canada, Japan, US, RoW
Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Teclistamab, JNJ-64007957
Janssen Research & Development, LLC, Janssen Research & Development, LLC
Multiple Myeloma
08/25
12/28
MajesTEC-9, NCT05572515: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
3
590
Europe, Canada, Japan, US, RoW
Teclistamab, JNJ-64007957, Pomalidomide, Bortezomib, Dexamethasone, Carfilzomib
Janssen Research & Development, LLC
Relapsed or Refractory Multiple Myeloma
10/25
08/31
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1572
Europe, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
MajesTEC-7, NCT05552222 / 2022-000909-28: A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Recruiting
3
1590
Europe, Canada, Japan, RoW
Teclistamab, JNJ-64007957, Daratumumab, Lenalidomide, Dexamethasone, Talquetamab, JNJ-64407564
Janssen Research & Development, LLC, Janssen Research & Development, LLC
Multiple Myeloma
04/31
10/33
2022-001186-12: Clinical trial for patients with newly diagnosed multiple myeloma to evaluate safety, tolerability and efficacy of teclistamab in combination with daratumumab, lenalidomide, dexamethasone with or without bortezomib as induction therapy, and maintenance therapy with teclistamab and lenalidomide after autologous stem cell transplantation. Klinische Studie für Patienten mit neu diagnostiziertem multiplem Myelom zur Untersuchung der Sicherheit, Verträglichkeit und Wirksamkeit von Teclistamab in Kombination mit Daratumumab, Lenalidomid, Dexamethason mit oder ohne Bortezomib in der Induktionstherapie, sowie in der Erhaltungstherapie mit Teclistamab und Lenalidomid nach einer autologen (körpereigenen) Stammzelltransplantation.

Not yet recruiting
2
50
Europe
JNJ-64007957, Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20), JNJ-64007957, JNJ-54767414, Solution for injection, Darzalex
Ruprecht-Karls-University Heidelberg, Medical Faculity, represented by University Hospital Heidelberg, Janssen Research & Development, LLC
Newly Diagnosed Multiple Myeloma in patients eligible for stem cell transplantation Neu diagnostiziertes multiples Myelom bei Patienten, die für eine Stammzelltransplantation geeignet sind, Newly Diagnosed Multiple Myeloma in patients eligible for stem cell transplantation Neu diagnostiziertes multiples Myelom bei Patienten, die für eine Stammzelltransplantation geeignet sind, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2022-000598-15: An open label, multicenter, Phase 2, pilot study, evaluating early treatment with bispecific T-cell redirectors (teclistamab and talquetamab) in the therapy of newly diagnosed high -risk multiple myeloma Estudio piloto fase 2, abierto y multicéntrico para evaluar la intervención temprana con anticuerpos biespecíficos redireccionadores de células T (teclistamab y talquetamab) en el tratamiento de primera línea de mieloma múltiple de alto riesgo de nuevo diagnóstico

Not yet recruiting
2
30
Europe
Darzalex, Velcade, Lenalidomida 25 mg, Dexamethasone, Lenalidomida 20 mg, Lenalidomida 15 mg, Lenalidomida 10 mg, Lenalidomida 5 mg, Teclistamab 30mg, Teclistamab 150mg, Talquetamab 3mg, Talquetamab 40mg, L01XC24, L01XX32, L04AX04, H02AB02, JNJ-64007957, JNJ-64407564, Solution for injection, Powder for solution for injection, Capsule, hard, Tablet, Darzalex 1.800 mg, Velcade 3.5mg, TECVAYLI
PETHEMA Foundation, Janssen
Multiple Myeloma Mieloma múltiple, Multiple Myeloma Mieloma múltiple, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
IFm2022-01, NCT06353022: Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

Not yet recruiting
2
103
Europe
Teclistamab, No more information, Talquetamab, Lenalidomide, Bortezomib, Daratumumab, Dexamethasone
Nantes University Hospital, Janssen Pharmaceutica
Multiple Myeloma
04/26
06/30
NCT06352866: Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Not yet recruiting
2
20
US
Siltuximab, Teclistamab(FDA-approved)
Jack Khouri
Multiple Myeloma, Cytokine Release Syndrome, Refractory Multiple Myeloma, Immune Effector Cell Associated Neurotoxicity Syndrome
04/25
12/25
NCT06171685: Horizon Adaptive Platform Trial Evaluating Therapies in RRMM

Not yet recruiting
2
300
NA
Teclistamab, Investigational Agent
Multiple Myeloma Research Consortium
Relapse Multiple Myeloma, Refractory Multiple Myeloma
07/29
07/30
OPTec, NCT05972135: Outpatient Administration of Teclistamab for Multiple Myeloma

Recruiting
2
50
US
Teclistamab, (TECVAYLI™), Tocilizumab
SCRI Development Innovations, LLC, Janssen Research & Development, LLC
Multiple Myeloma
01/25
02/25
GEM-TECTAL, NCT05849610: Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

Recruiting
2
30
Europe
Daratumumab, Bortezomib, Lenalidomide, Teclistamab, JNJ-64007957, Talquetamab, JNJ-64407564
PETHEMA Foundation, Janssen Pharmaceutica
High-Risk de Novo Multiple Myeloma
01/25
07/29
MajesTEC-1, NCT04557098 / 2016-002122-36: A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Hourglass Jun 2023 - Jun 2023 : Presentation of data form MajesTEC-1 trial for multiple myeloma at EHA 2023
Checkmark Data from MajesTEC-1 trial for multiple myeloma
Dec 2021 - Dec 2021: Data from MajesTEC-1 trial for multiple myeloma
Active, not recruiting
2
194
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957
Janssen Research & Development, LLC
Hematological Malignancies
03/25
09/25
IFM 2021-01, NCT05572229: Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma

Not yet recruiting
2
74
NA
Teclistamab, JNJ-64007957, Daratumumab, Lenalidomide
University Hospital, Lille, Janssen Pharmaceutica N.V., Belgium
Multiple Myeloma
05/25
09/30
NCT05932680: Limited-duration Teclistamab

Recruiting
2
75
US
Off Drug Surveillance
Abramson Cancer Center at Penn Medicine
Myeloma Multiple
06/25
01/27
MajesTEC-5, NCT05695508: GMMG-HD10 / DSMM-XX / 64007957MMY2003,

Recruiting
2
70
Europe
Teclistamab (Tec), JNJ-64007957, Daratumumab, Dexamethasone, Lenalidomide, Bortezomib
University of Heidelberg Medical Center, Janssen Research & Development, LLC, Deutsche Studiengruppe Multiples Myelom (DSMM)
Multiple Myeloma
10/26
10/27
MASTER-2, NCT05231629: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

Recruiting
2
300
US
Dara-VRd intensification, Dara-R maintenance, darzalex, velcade, revlimid, dexamethasone, AHCT intensification, Dara-R maintenance, melphalan, darzalex, revlimid, AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance, melphalan, teclistamab, darzalex, AHCT intensification, Dara-R consolidation, Dara-R maintenance, Dara-VRd induction
University of Alabama at Birmingham, Janssen Scientific Affairs, LLC
Multiple Myeloma
12/26
12/27
REVIVE, NCT06100237: Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma ( Study)

Recruiting
2
50
US
Teclistamab, Talquetamab, Daratumumab SC
Carl Ola Landgren, MD, PhD, Janssen Scientific Affairs, LLC
Multiple Myeloma
12/28
12/29
Immuno-PRISM, NCT05469893: (PRecision Intervention Smoldering Myeloma)

Recruiting
2
51
US
Teclistamab, JNJ-64007957, Lenalidomide, Revlimid, Dexamethasone
Irene Ghobrial, MD, Janssen Research & Development, LLC
High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
07/30
07/30
2016-002122-36: An Open label Study of Teclistamab in Subjects with Relapsed and Refractory Multiple Myeloma

Ongoing
1/2
228
Europe, RoW
JNJ-64007957, JNJ-64007957, Solution for infusion, Solution for injection
Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development, LLC, JANSSEN CILAG SPA
Relapsed or Refractory Multiple Myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
2019-000330-19: A Clinical Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma Estudio clínico de regímenes de daratumab subcutáneo en combinación con anticuerpos de redirección de células T biespecíficos para el tratamiento de sujetos con mieloma múltiple.

Not yet recruiting
1/2
100
Europe
JNJ-64007957, Vehicle 001, JNJ-64407564, Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20), JNJ-64007957, Vehicle 001, JNJ-64407564, JNJ-54767414, Solution for infusion, Solution for injection
Janssen-Cilag International NV, Janssen Research & Development, LLC
Multiple myeloma Mieloma múltiple, Bone marrow cancer Cáncer de médula ósea, Diseases [C] - Cancer [C04]
 
 
NCT04696809: A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Active, not recruiting
1/2
40
Japan
Teclistamab, JNJ-64007957
Janssen Pharmaceutical K.K.
Hematologic Malignancies
03/25
03/25
RedirecTT-1, NCT04586426: A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
1/2
208
Europe, Canada, Japan, US, RoW
Talquetamab, JNJ-64407564, Teclistamab, JNJ-64007957, Daratumumab
Janssen Research & Development, LLC
Multiple Myeloma
06/25
08/25
MajesTEC-1, NCT03145181 / 2016-002122-36: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

Checkmark Results for relapsed/recurrent multiple myeloma at ASCO 2021
Jun 2021 - Jun 2021: Results for relapsed/recurrent multiple myeloma at ASCO 2021
Checkmark Presentation of data from trial in 1L r/r multiple myeloma at ASCO 2020
May 2020 - May 2020: Presentation of data from trial in 1L r/r multiple myeloma at ASCO 2020
Recruiting
1
282
Europe, US
Teclistamab (IV), JNJ-64007957, Teclistamab(SC)
Janssen Research & Development, LLC, Janssen Research & Development, LLC, JANSSEN CILAG SPA
Hematological Malignancies
11/21
07/26
MajesTEC-10, NCT06425991: A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
1
100
US, RoW
Teclistamab, JNJ-64007957
Janssen Research & Development, LLC
Relapsed or Refractory Multiple Myeloma
07/25
01/27
MajesTEC-2, NCT04722146: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Checkmark MajesTEC-2 study of Tecvayli combo Darzalex Faspro and lenalidomide
Dec 2022 - Dec 2022: MajesTEC-2 study of Tecvayli combo Darzalex Faspro and lenalidomide
Active, not recruiting
1
140
Europe, US, RoW
Teclistamab, JNJ-64007957, Daratumumab, Pomalidomide, Lenalidomide, Bortezomib, Nirogacestat
Janssen Research & Development, LLC
Multiple Myeloma
10/24
02/25
NCT06465316: Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Hard-to-Treat Multiple Myeloma

Not yet recruiting
1
20
NA
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Iberdomide, CC 220, CC-220, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Teclistamab, JNJ 64007957, JNJ-64007957, JNJ64007957, Teclistamab-cqyv, Tecvayli
National Cancer Institute (NCI)
Multiple Myeloma
01/27
01/27
TRIMM-2, NCT04108195: A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Active, not recruiting
1
290
Europe, Canada, US
Daratumumab, JNJ-54767414, Darzalex, Talquetamab, JNJ-64407564, Teclistamab, JNJ-64007957, Pomalidomide
Janssen Research & Development, LLC
Multiple Myeloma
09/24
08/25
TRIMM-3, NCT05338775: A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
1
152
Europe, US
Talquetamab, Teclistamab, PD-1 Inhibitor
Janssen Research & Development, LLC
Relapsed/ Refractory Multiple Myeloma
09/24
11/25
BISPEMM, NCT06359067: A Real-World Study of Bispecific Antibodies in Multiple Myeloma

Completed
N/A
600
Europe
Treated by bispecific antibodies, teclistamab or elranatamab in usual care, Not treated by bispecific antibodies in usual care
Assistance Publique - Hôpitaux de Paris
Multiple Myeloma
12/23
12/23
NCT05161598: Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)

No Longer Available
N/A
NA
Teclistamab, JNJ-64007957
Janssen Research & Development, LLC
Multiple Myeloma
 
 
REALiTEC, NCT06285318: A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

Recruiting
N/A
280
Europe, RoW
Teclistamab, TECVAYLI, Talquetamab, TALVEY
Janssen-Cilag Ltd.
Relapsed/Refractory Multiple Myeloma (RRMM)
11/24
11/24
ResisTec, NCT05945524: Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination

Not yet recruiting
N/A
100
NA
Bone marrow sampling
University Hospital, Toulouse
Multiple Myeloma
05/26
05/26
TEC-CARE, NCT06062537: Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients

Recruiting
N/A
200
Europe
Intergroupe Francophone du Myelome, Janssen-Cilag Ltd.
Multiple Myeloma
09/26
09/26

Download Options